David TAN

My primary clinical and research interests are in gynaecological (ovarian, cervical, endometrial) cancer and drug development. My work is focused on the development of biomarkers and novel anti-cancer therapeutic agents.

david_sp_tan[at]nuhs.edu.sg

Affiliations

Research

Publications

Affiliations

Senior Consultant Medical Oncologist, Dept of Haematology-Oncology, National University Cancer Institute
Associate Professor, Dept of Medicine, Yong Loo Lin School of Medicine, NUS
Principal Investigator, Cancer Science Institute of Singapore.

Research

My research is focused on the development of biomarkers and novel therapeutic agents in gynaecological cancers. Gynaecological cancers represent a highly heterogenous group of diseases, with each tumour subtype harbouring specific molecular aberrations and presenting its own unique clinical challenges. Understanding the genetic and tumour microenvironmental factors that drive these cancers will be crucial for the development of new therapeutic strategies. By elucidating the genomic/ molecular profiles of gynaecological cancers using a variety of high-throughput analytic platforms, our aim is to identify aberrant molecular pathways that may potentially be exploited for therapeutic development. For example, Poly (ADP-ribose) polymerase (PARP) is a family of proteins involved in a number of cellular processes involving mainly DNA repair, and PARP inhibitors and DNA-damaging agents have been shown to be particularly effective in the treatment of ovarian cancers with defects in the homolgous recombination DNA repair pathway. We are currently developing biomarkers that will facilitate the identification of patients whose tumours harbour deficiencies in these DNA repair pathways.

Publications

1. Nagao, Shoji, Fujiwara, Keiichi, Yamamoto, Kouji, Tanabe, Hiroshi, Okamoto, Aikou, Takehara, Kazuhiro, Saito, Motoaki, Fujiwara, Hiroyuki, Tan, David SP, Yamaguchi, Satoshi, Adachi, Sosuke, Kikuchi, Akira, Hirasawa, Takeshi, Yokoi, Takeshi, Nagai, Tomonori, Sato, Toyomi, Kamiura, Shoji, Fujishita, Akira, Loong, Wong Wai, Chan, Karen, Syks, Peter, Olawaye, Alexsander, Ryu, Sang-Young, Shigeta, Hiroyuki, Kondo, Eiji, Yokoyama, Yoshihito, Matsumoto, Takashi, Hasegawa, Kosei, Enomoto, Takayuki Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial. NEJM Evidence 2 2023 (5). https://doi.org/10.1056/evidoa2200225

2. Loh J, Wu J, Chieng J, Chan A, Yong WP, Sundar R, Lee SC, Wong A, Lim JSJ, Tan David SP, Soo R, Goh BC, Tai BC, Chee CE. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials. Br J Cancer. 2023 Apr;128(8):1514-1520.

3. Pujade-Lauraine E, Tan David SP, Leary A, Mirza MR, Enomoto T, Takyar J, Nunes AT, Chagüi JDH, Paskow MJ, Monk BJ. Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review. Gynecol Oncol. 2022 S0090-8258(22)00552-2.

4. Lim, JSJ, Wong, ALA, Ow, SGW, Ngoi, NYL, Chan, GHJ, Ang, YLE, Chong, WQ, Lim, SE, Lim, YW, Lee, M, Choo, JRE, Tan, HL, Yong, WP, Soo, RA, Tan, David SP, Chee, CE, Sundar, R, Yadav, K, Jain, S, Wang, L, Tai, BC, Goh, BC, Lee, SC Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research 2022 28 (11) : 2248-2256.

5. Hoppe MM, Jaynes P, Wardyn JD, Upadhyayula SS, Tan TZ, Lie S, Lim DGZ, Pang BNK, Lim S, P S Yeong J, Karnezis A, Chiu DS, Leung S, Huntsman DG, Sedukhina AS, Sato K, Topp MD, Scott CL, Choi H, Patel NR, Brown R, Kaye SB, Pitt JJ, Tan David SP, Jeyasekharan AD. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO Mol Med. 2021 (5):e13366.

6. Yap TA, Tan David SP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discov. 2021 ;11(1):80-91.

7. National University Cancer Institute of Singapore (NCIS) Workflow Team. A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore. Ann Oncol. 2020 ;31(7):840-843.

8. Tan TZ, Ye J, Yee CV, Lim D, Ngoi NYL, Tan David SP, Huang RY. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine. 2019 ;50:203-210.

9. Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, Tan WL, Peethala PC, Soe MY, Tan David SP, Padmanabhan N, Baloglu E, Shacham S, Tan P, Koeffler HP, Yong WP. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep. 2018 16;8(1):12248.

10. Hoppe MM, Sundar R, Tan David SP, Jeyasekharan AD. Biomarkers for Homologous Recombination Deficiency in Cancer. J Natl Cancer Inst. 2018 1;110(7):704-713.